Pay in 4 interest-free payments of $5.82 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Shlipak MG, Matsushita K, Arnlov J, et al
Test Results: 4-7 days
This reflects the evolving focus on combination therapies to enhance efficacy and broaden treatment options in obesity care SKU- Interactive Data Analysis Dashboard Company Analysis Dashboard for high growth potential opportunities Research Analyst Access for customization & queries Competitor Analysis with Interactive dashboard Latest News, Updates & Trend analysis Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking Data collection and base year analysis are done using data collection modules with large sample sizes
Warning THE GOODS OFFERED BY THE SELLER IS INTENDED FOR SCIENTIFIC AND DEVELOPMENT PURPOSES ONLY
A Multicentre, Randomised, Double-Blind, Placebo Controlled, Phase II Study to Evaluate the Safety and Efficacy of Subcutaneous Bioresorbable Implants of Afamelanotide (CUV1647) for the Prophylactic Treatment of Pre-Cancerous Skin Lesions of the Head, Forearms and Hands in Immune Compromised, Organ Transplant Patients (Report)
